Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Scientific Papers of Interest
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Scientific Papers of Interest
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2016 February
  • Home
  • Archive for February, 2016

Biosortia Pharmaceuticals Introduction JLABS – San Diego

  • February 25 2016

San Diego, California (February 25, 2016) – A brief explanation of what Biosortia does, how is it achieved, and why it is meaningful. Drug discovery directly from the chemistry of unculturable aquatic microorganisms in situ. ### About Biosortia Pharmaceuticals – Biosortia has a proven and unique ability to obtain unculturable aquatic microbial consortia from the natural environment in

Continue Reading

BIOSORTIA CONTRACT GIVES RESEARCHERS ACCESS TO NATURAL PRODUCT CHEMISTRY FOR DRUG DISCOVERY EFFORTS

  • February 22 2016

Columbus, Ohio (February 22, 2016) – Biosortia Pharmaceuticals announces today a contract with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) that gives the institution’s cancer researchers access to novel natural product chemistry for the purpose of discovering and developing cancer-fighting therapeutics.

Continue Reading

RSS Industry News

  • Practical lessons from microbiome citizen-science projects May 4 2026
  • Probiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding May 4 2026
  • A Muribaculaceae-enriched microbiota exacerbates TLR4-dependent Acinetobacter baumannii-induced hyperinflammatory sepsis April 30 2026
  • Navigating the translational labyrinth of the gut microbiota April 29 2026
  • Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial April 27 2026
  • Community context reshapes microbial proteomes and reduces functional overlap April 24 2026
  • Author Correction: Commensal yeast promotes Salmonella Typhimurium virulence April 24 2026
  • The network structure of cross-feeding impacts microbial community diversity under growth-inhibiting stresses April 23 2026
  • Ketogenic diet exacerbates DSS-induced colitis through a β-hydroxybutyrate-Thomasclavelia spiroformis-γδ17 T cell axis in mice April 23 2026
  • Human milk oligosaccharide mediates mutualism between Escherichia coli and Bifidobacterium bifidum April 22 2026
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • Polypeptides synthesized by common bacteria in the human gut improve rodent metabolism
  • Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound
  • Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2026. All Rights Reserved.